Libre Del Cigarrillo: Development of an mHealth Smoking Cessation App to Extend Reach of a Validated Smoking Cessation Intervention for Spanish-speaking Smokers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Marilyn Horta, PhD
- Phone Number: 813-745-3861
- Email: Marilyn.Horta@moffitt.org
Study Contact Backup
- Name: Maria Almendares
- Phone Number: 813-745-7863
- Email: Maria.Almendares@moffitt.org
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
Sub-Investigator:
- Steven Sutton, PhD
-
Sub-Investigator:
- Cathy Meade, PhD
-
Principal Investigator:
- Vani Simmons, PhD
-
Sub-Investigator:
- Christine Vinci, PhD
-
Sub-Investigator:
- Jennifer Vidrine, PhD
-
Sub-Investigator:
- Ursula Martinez, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Self-identify as Hispanic/Latinx.
- 18+ Years of age.
- Monolingual Spanish-speaking, or bilingual Spanish-English and prefer educational health materials in Spanish.
- Have been smoking at least 5 cigarettes per week over the past year
- Not currently enrolled in a face-to-face or virtual smoking cessation program.
Exclusion Criteria:
- A household member enrolled in the study.
- Prior participation in the LDC randomized controlled trial.
- Prior use of the NCI SmokefreeTXT program.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1: Smartphone app
Participants receive access to the finalized Libre del Cigarrillo smoking-cessation app.
|
Participants receive full access to the culturally adapted cessation app.
|
|
Experimental: Arm 2: Printed booklets
Participants receive the culturally tailored Libre del Cigarrillo printed self-help booklets.
|
The validated Spanish-language booklet series previously shown to increase long-term abstinence.
|
|
Experimental: Arm 3: SmokefreeTXT
Participants receive NCI's automated Spanish-language SmokefreeTXT text-messaging cessation program.
|
NCI Text-Messaging Program
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Usability - System Usability Scale
Time Frame: Up to 18 Months
|
Participants' perceptions of the app's usability in the app arm will be measured using 10 items on a 5-point Likert Scale.
Scores range from 0 to 100, with higher scores indicating better usability.
|
Up to 18 Months
|
|
Acceptability - Client Satisfaction Questionnaire (CSQ)
Time Frame: Up to 18 Months
|
Participants' satisfaction with the LDC app will be measured using the Client Satisfaction Questionnaire (CSQ).
The questionnaire consists of 8 items rated on a 4-point Likert scale, with higher scores indicating greater overall satisfaction.
|
Up to 18 Months
|
|
Feasibility - Screening Rate
Time Frame: Up to 18 Months
|
Number of potential participants screened to participate in the study.
|
Up to 18 Months
|
|
Feasibility - Enrollment Rate
Time Frame: Up to 18 Months
|
Number of screened eligible participants who enroll in the study.
|
Up to 18 Months
|
|
Feasibility - Baseline Assessment Completion
Time Frame: Baseline
|
Number of enrolled participants who complete all baseline questionnaires.
|
Baseline
|
|
Feasibility - Retention at 18 Months
Time Frame: Up to 18 months
|
Number of participants in each of the arms that completed the 18-month follow-up assessment.
|
Up to 18 months
|
|
Feasibility - Biochemical Verification
Time Frame: Up to 18 months
|
Number of participants self-reporting abstinence who returned saliva samples for cotinine verification.
|
Up to 18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Vani Simmons, PhD, Moffitt Cancer Center
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MCC-23497
- R34CA297368 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.